RxDoctor Payments Data

Tuan Nguyen, MD

Internal Medicine · Norcross, GANPI 1386756955

Payments from drug & device makers

$8,088in general payments, 2019–2025

Across 446 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$691
  • Sanofi-aventis U.S. LLC$564
  • Amarin Pharma, Inc.$514
  • AstraZeneca$505
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$8,074100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,088 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$43,447
Medicare patients
91
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$197,739
EliquisApixaban170$79,922
CreonLipase/Protease/Amylase35$48,951
XareltoRivaroxaban95$43,182
LinzessLinaclotide36$33,966
JanuviaSitagliptin Phosphate28$32,428
MyrbetriqMirabegron46$29,731
RestasisCyclosporine22$26,198
VemlidyTenofovir Alafenamide13$18,228
TradjentaLinagliptin14$17,621
TrulicityDulaglutide15$17,145
VascepaIcosapent Ethyl22$16,367
Breo ElliptaFluticasone/Vilanterol14$14,191
Diclofenac Sodium200$10,308
Metformin Er GastricMetformin Hcl25$9,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$229$221,137178 claims
AbbVieCreon, Linzess, Restasis, Combigan$358$112,577104 claims
PfizerEliquis$298$79,922170 claims
Johnson & JohnsonXarelto$24$43,18295 claims
MerckJanuvia$34$32,42828 claims
GSKBreo Ellipta, Trelegy Ellipta$46$22,68527 claims
GileadVemlidy$191$18,22813 claims
Lilly USA, LLCTrulicity$691$17,14515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →